Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses

The Lancet Psychiatry

Volumn 4, Issue 9, 2017, Pages 694-705

  Zhu, Yikang ^a,b   Krause, Marc ^a   Huhn, Maximilian ^a   Rothe, Philipp ^a   Schneider Thoma, Johannes ^a   Chaimani, Anna ^c,d,e   Li, Chunbo ^b   Davis, John M ^f,g   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PARIS DESCARTES UNIVERSITY   (France)

^e Cochrane France ^*  (France)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; FLUPENTIXOL; HALOPERIDOL; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PROLACTIN; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MENTAL PATIENT; META ANALYSIS; NEGATIVE SYNDROME; NETWORK META-ANALYSIS; PARKINSONISM; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN RELEASE; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEDATION; SYSTEMATIC REVIEW; WEIGHT GAIN; CLASSIFICATION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; HUMANS; NETWORK META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 85025177053     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30270-5     Document Type: Article

References (72)

1. WHO. The WHO world health report: new understanding, new hope, 2001, World Health Organization, Geneva.
2. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1603–1658.
3. Sanger, TM, Lieberman, JA, Tohen, M, Grundy, S, Beasley, C Jr, Tollefson, GD, Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 156 (1999), 79–87.
4. McCleery, A, Ventura, J, Kern, RS, et al. Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment. Schizophr Res 157 (2014), 33–39.
5. Torres, US, Duran, FL, Schaufelberger, MS, et al. Patterns of regional gray matter loss at different stages of schizophrenia: a multisite, cross-sectional VBM study in first-episode and chronic illness. Neuroimage Clin 12 (2016), 1–15.
6. Li, T, Wang, Q, Zhang, J, et al. Brain-wide analysis of functional connectivity in first-episode and chronic stages of schizophrenia. Schizophr Bull 43 (2017), 436–448.
7. Perkins, D, Lieberman, J, Gu, H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 185 (2004), 18–24.
8. Perkins, DO, Gu, H, Boteva, K, Lieberman, JA, Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162 (2005), 1785–1804.
9. Lieberman, J, Jody, D, Geisler, S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50 (1993), 369–376.
10. Jager, M, Riedel, M, Messer, T, et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 257 (2007), 47–53.
11. Schennach, R, Riedel, M, Musil, R, Moller, HJ, Treatment response in first-episode schizophrenia. Clin Psychopharmacol Neurosci 10 (2012), 78–87.
12. Zhu, YK, Li, CB, Huhn, M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharamcol, 2017 published online June 29. DOI:10.1016/j.euroneuro.2017.06.011.
13. Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382 (2013), 951–962.
14. Leucht, S, Leucht, C, Huhn, M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry, 2017 published online May 25. DOI:10.1176/appi.ajp.2017.16121358.
15. Crossley, NA, Constante, M, McGuire, P, Power, P, Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196 (2010), 434–439.
16. Zhang, JP, Gallego, JA, Robinson, DG, Malhotra, AK, Kane, JM, Correll, CU, Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 16 (2013), 1205–1218.
17. Tyrer, P, Kendall, T, The spurious advance of antipsychotic drug therapy. Lancet 373 (2009), 4–5.
18. Zohar, J, Stahl, S, Moller, HJ, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 25 (2015), 2318–2325.
19. Salanti, G, Del Giovane, C, Chaimani, A, Caldwell, DM, Higgins, JP, Evaluating the quality of evidence from a network meta-analysis. PLoS One, 9, 2014, e99682.
20. Cornell, JE, The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses. Ann Intern Med 162 (2015), 797–798.
21. Hutton, B, Catala-Lopez, F, Moher, D, The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. Med Clin (Barc) 147 (2016), 262–266 (in Spanish).
22. Gardner, DM, Murphy, AL, O'Donnell, H, Centorrino, F, Baldessarini, RJ, International consensus study of antipsychotic dosing. Am J Psychiatry 167 (2010), 686–693.
23. Kay, SR, Fiszbein, A, Opler, LA, The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987), 261–276.
24. Overall, JE, Gorham, DR, The brief psychiatric rating scale. Psychol Rep 10 (1962), 799–812.
25. Hyde, CE, The Manchester scale. A standardised psychiatric assessment for rating chronic psychotic patients. Br J Psychiatry Suppl 7 (1989), 45–48.
26. Guy, W, ECDEU Assessment Manual for Psychopharmacology, 1976, US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD.
27. Elbourne, DR, Altman, DG, Higgins, JP, Curtin, F, Worthington, HV, Vail, A, Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31 (2002), 140–149.
28. Woodhead, M, 80% of China's clinical trial data are fraudulent, investigation finds. BMJ, 355, 2016, i5396.
29. Center for Food and Drug Inspection of CFDA. Drug clinical trial data verification situation report [in Chinese]. www.cfdi.org.cn/resource/news/7713.html (accessed July 12, 2017).
30. Higgins, JP, Green, S, Cochrane handbook for systematic reviews of interventions, version 5.1.0, 2011, John Wiley & Sons, Chichester.
31. Furukawa, TA, Salanti, G, Atkinson, LZ, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open, 6, 2016, e010919.
32. Cohen, J, Statistical power analysis for the behavioral sciences, 2nd edn., 1988, Lawrence Earlbaum Associates, Mahwah, NJ.
33. White, IR, Network meta-analysis. Stata J 15 (2015), 951–985.
34. Chaimani, A, Salanti, G, Visualizing assumptions and results in network meta-analysis: the network graphs package. Stata J 15 (2015), 905–950.
35. Salanti, G, Ades, AE, Ioannidis, JP, Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64 (2011), 163–171.
36. Salanti, G, Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3 (2012), 80–97.
37. Rhodes, KM, Turner, RM, Higgins, JP, Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol 68 (2015), 52–60.
38. Turner, RM, Davey, J, Clarke, MJ, Thompson, SG, Higgins, JP, Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 41 (2012), 818–827.
39. Bucher, HC, Guyatt, GH, Griffith, LE, Walter, SD, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50 (1997), 683–691.
40. Dias, S, Welton, NJ, Caldwell, DM, Ades, AE, Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29 (2010), 932–944.
41. Higgins, JPT, Jackson, D, Barrett, JK, Lu, G, Ades, AE, White, IR, Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3 (2012), 98–110.
42. Robinson, DG, Woerner, MG, Napolitano, B, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 163 (2006), 2096–2102.
43. Chaimani, A, Higgins, JP, Mavridis, D, Spyridonos, P, Salanti, G, Graphical tools for network meta-analysis in STATA. PLoS One, 8, 2013, e76654.
44. The Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. Br J Psychiatry 150 (1987), 334–338.
45. Amr, M, Lakhan, SE, Sanhan, S, et al. Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial. Int Arch Med, 6, 2013, 47.
46. Brewer, WJ, Yucel, M, Harrison, BJ, et al. Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Aust NZ J Psychiatry 41 (2007), 129–135.
47. Chaudhuri, BP, Bhagabati, D, Medhi, D, Risperidone versus haloperidol in acute and transient psychotic disorder. Indian J Psychiatry 42 (2000), 280–290.
48. Crespo-Facorro, B, Perez-Iglesias, R, Ramirez-Bonilla, M, Martinez-Garcia, O, Llorca, J, Luis Vazquez-Barquero, J, A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry 67 (2006), 1511–1521.
49. Emsley, RA, Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 25 (1999), 721–729.
50. Fagerlund, B, Mackeprang, T, Gade, A, Glenthoj, BY, Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 9 (2004), 364–374.
51. Gafoor, R, Landau, S, Craig, TK, Elanjithara, T, Power, P, McGuire, P, Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. J Clin Psychopharmacol 30 (2010), 600–606.
52. Gallhofer, B, Jaanson, P, Mittoux, A, Tanghoj, P, Lis, S, Krieger, S, Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 40 (2007), 275–286.
53. Lee, SM, Chou, YH, Li, MH, Wan, FJ, Yen, MH, Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients. J Psychiatr Res 42 (2008), 328–335.
54. Lieberman, JA, Tollefson, G, Tohen, M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160 (2003), 1396–1404.
55. McEvoy, JP, Lieberman, JA, Perkins, DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164 (2007), 1050–1060.
56. Möller, HJ, Riedel, M, Jäger, M, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 11 (2008), 985–997.
57. Robinson, DG, Gallego, JA, John, M, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull 41 (2015), 1227–1236.
58. San, L, Arranz, B, Perez, V, et al. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Res 200 (2012), 693–701.
59. Sikich, L, Frazier, JA, McClellan, J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165 (2008), 1420–1431.
60. Svestka, J, Synek, O, Zourkova, A, Olanzapine versus risperidone in first-episode schizophrenic and schizoform disorders: a double-blind comparison. Eur Neuropsychopharmacol, 13(suppl 4), 2003, S291.
61. Fleischhacker, WW, Derks, E, Kahn, RS, Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST. Schizophr Res 138 (2012), 39–40.
62. Kahn, RS, Fleischhacker, WW, Boter, H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (2008), 1085–1097.
63. Robinson, DG, Woerner, MG, Alvir, JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156 (1999), 544–549.
64. Lieberman, JA, Phillips, M, Gu, H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28 (2003), 995–1003.
65. Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373 (2009), 746–758.
66. Thomas, JE, Caballero, J, Harrington, CA, The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol 13 (2015), 681–691.
67. Buchanan, RW, Kreyenbuhl, J, Kelly, DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36 (2010), 71–93.
68. De Hert, M, Yu, W, Detraux, J, Sweers, K, van Winkel, R, Correll, CU, Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26 (2012), 733–759.
69. Geddes, J, Freemantle, N, Harrison, P, Bebbington, P, Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000), 1371–1376.
70. Oosthuizen, P, Emsley, R, Jadri Turner, H, Keyter, N, A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol 7 (2004), 125–131.
71. Zimbroff, DL, Kane, JM, Tamminga, CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154 (1997), 782–791.
72. Davis, JM, Chen, N, Glick, ID, A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 (2003), 553–564.